Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 182 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016', provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
- The report reviews pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics and enlists all their major and minor projects
- The report assesses Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 10
Therapeutics Development 11
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview 11
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis 12
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies 13
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes 15
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies 19
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes 21
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development 22
Altor BioScience Corporation 22
APIM Therapeutics AS 23
Astellas Pharma Inc. 24
Bavarian Nordic A/S 25
BioCancell Ltd 26
Celgene Corporation 27
Cold Genesys, Inc. 28
F. Hoffmann-La Roche Ltd. 29
Heat Biologics, Inc. 30
Merck & Co., Inc. 31
Spectrum Pharmaceuticals, Inc. 32
Taris Biomedical LLC 33
UroGen Pharmaceuticals, Ltd. 34
Vakzine Projekt Management GmbH 35
Vaxiion Therapeutics, Inc. 36
Viralytics Ltd. 37
Viventia Bio Inc. 38
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
ALT-801 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ALT-803 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
apaziquone - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
atezolizumab - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ATX-101 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
BC-819 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Biologic for Superficial Bladder Cancer - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
cavatak - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
CG-0070 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
CV-301 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
DAB-389EGF - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
docetaxel - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Drug for NMIBC - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
erlotinib hydrochloride - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
gemcitabine hydrochloride - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
imiquimod - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
lenalidomide - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
mitomycin SR - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Monoclonal Antibody to Antagonize EGFR for Superficial Bladder Cancer - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
nitroxoline - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
P-MAPA - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
paclitaxel - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
pembrolizumab - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
rAd-IFN - Drug Profile 155
Product Description 155
Mechanism Of Action 155
R&D Progress 155
sirolimus albumin-bound - Drug Profile 157
Product Description 157
Mechanism Of Action 157
R&D Progress 157
Vaccine for Oncology - Drug Profile 159
Product Description 159
Mechanism Of Action 159
R&D Progress 159
VAX-014 - Drug Profile 160
Product Description 160
Mechanism Of Action 160
R&D Progress 160
VB-4845 - Drug Profile 161
Product Description 161
Mechanism Of Action 161
R&D Progress 161
vesigenurtucel-L - Drug Profile 163
Product Description 163
Mechanism Of Action 163
R&D Progress 163
VPM-1002 - Drug Profile 168
Product Description 168
Mechanism Of Action 168
R&D Progress 168
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects 170
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products 171
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones 172
Featured News & Press Releases 172
Aug 10, 2016: TARIS Biomedical Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Bladder Cancer 172
May 06, 2016: Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research (AUA) in San Diego, California, May 6-10, 2016 172
May 05, 2016: UroGen Pharma Announces Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association's 2016 Annual Meeting 173
Apr 07, 2016: Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestone 174
Feb 25, 2016: Heat Biologics Provides Update on Its HS-410 Phase II Monotherapy Bladder Cancer Trial Arm 174
Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation) 174
Feb 10, 2016: FDA Lifts Heat Biologics Partial Clinical Hold 175
Feb 03, 2016: Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial 175
Jan 26, 2016: Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference 175
Jan 13, 2016: UroGen Pharma Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset 176
Nov 06, 2015: Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer Annual Meeting 177
Nov 03, 2015: Results of Heat Biologics' HS-410 Phase 1 Safety Trial in Non-Muscle Invasive Bladder Cancer to be Presented at SITC Annual Meeting 178
Oct 26, 2015: Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer Following SPA Agreement 178
Aug 17, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer 179
Jul 02, 2015: Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer 180
Appendix 181
Methodology 181
Coverage 181
Secondary Research 181
Primary Research 181
Expert Panel Validation 181
Contact Us 181
Disclaimer 182

List of Tables

Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H2 2016 11
Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H2 2016 22
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by APIM Therapeutics AS, H2 2016 23
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Astellas Pharma Inc., H2 2016 24
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bavarian Nordic A/S, H2 2016 25
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by BioCancell Ltd, H2 2016 26
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Celgene Corporation, H2 2016 27
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H2 2016 28
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc., H2 2016 30
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Merck & Co., Inc., H2 2016 31
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 32
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Taris Biomedical LLC, H2 2016 33
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 34
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vakzine Projekt Management GmbH, H2 2016 35
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vaxiion Therapeutics, Inc., H2 2016 36
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viralytics Ltd., H2 2016 37
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Bio Inc., H2 2016 38
Assessment by Monotherapy Products, H2 2016 39
Number of Products by Stage and Target, H2 2016 41
Number of Products by Stage and Mechanism of Action, H2 2016 44
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H2 2016 170
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H2 2016 171